Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 3/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.54 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.54 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.54 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937199 | 0.89 | MAPK9 (0.56) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL16416776 | 0.87 | MAPK9 (0.70) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL6931494 | 0.86 | MAPK14 (0.54) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL8327447 | 0.85 | GSK3B (0.53) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL6934803 | 0.85 | MAPK9 (0.54) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| Dimethylamine SCHEMBL8176050 | 0.85 | MAPK14 (0.52) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL6933720 | 0.85 | MAPK9 (0.52) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| SCHEMBL6936810 | 0.83 | MAPK9 (0.55) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| Butylamine SCHEMBL6931853 | 0.80 | MAPK14 (0.50) | MAPK9MAPK13MAPK14MAP4K4CSNK1D | |
| Butylamine SCHEMBL6933493 | 0.80 | MAPK14 (0.49) | MAPK9MAPK13MAPK14MAP4K4CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | claimed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | claimed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | MAPK9 1247/4885MAPK13 1577/4885MAPK14 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.